Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with lamivudine and stavudine: A 96- week randomized, controlled study

Clinical Infectious Diseases

Volumn 48, Issue 9, 2009, Pages 1323-1326

  McComsey, Grace ^a,b   Rightmire, Anna ^c   Wirtz, Victoria ^c   Yang, Rong ^c   Mathew, Marina ^c   McGrath, Donnie ^c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; LAMIVUDINE; RITONAVIR; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OLIGOPEPTIDE; PYRIDINE DERIVATIVE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BODY FAT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; INTERMETHOD COMPARISON; INTRAABDOMINAL FAT; LIPOATROPHY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBCUTANEOUS FAT; BODY COMPOSITION; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; STAVUDINE;

EID: 65549167364     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597776     Document Type: Article

References (12)

1. Mallon PW. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy. AIDS Rev 2007; 9:3-15.
2. Murphy RL, Sanne I, Calm P, et al. Dose-ranging, randomized, clinical trial ofatazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17:2603-14.
3. Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006;20:1813-21.
4. Sension M, Grinsztejn B, Molina J. Improvement in lipid profiles after 12 weeks of switching to atazanavir from boosted or unboosted protease inhibitors in patients with no previous PI virologic failure and hyper- lipidemia at baseline [abstract 858]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). 2005.
5. Moyle G. Continuation of BID boosted PI vs switch to once-daily ATV300/RTV for the management of lipodystrophy: 24 week interim analysis of metabolic and inflammatory parameters of the 96 week multicenter, open-label, randomized, prospective real study [abstract PS5/6]. In: Program and abstracts of the 11th European AIDS Conference (Madrid). 2007.
6. Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 2006; 42:273-80.
7. McGrath D, Frederick D, Wirtz V. Body composition changes in ARV- naive subjects treated with atazanavir on atazanavir/ritonavir-based once-daily HAART: 48-week CT and DEXA data [abstract 804]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). 2007.
8. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretro- viral-naive patients. J Acquir Immune Defic Syndr 2008;47:161-7.
9. Haubrich RH, Riddler S, DiRenzo G. Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI- and NNRTI-sparing regimens for initial treatment of HIV-1 infection [abstract 38]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). 2007.
10. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1- infected men starting therapy. AIDS 2003; 17:971-9.
11. Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nel- finavir or efavirenz plus dual nucleosides. AIDS 2005; 19:1807-18.
12. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations: women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 2003;34:58-61.